Biotech raises $128.7 million to continue its work on genetic medicines to reduce cardiovascular disease.

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

Scribe Therapeutics, a clinical-stage developer of gene therapies for heart disease, is seeking to raise as much as $107.2 million through a U.S. initial public offering. The Alameda, California-based ...

Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 ...

Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, ...

Scribe Therapeutics (Nasdaq: SCTX) visits the Nasdaq MarketSite in Times Square. Scribe is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to ...

Both colors are reduced.

The Kindle Scribe Without Front Light should be an ideal e-ink notebook, but it's limits are hard to ignore. Find out more in this review.